Moshe Mittelman

Publication Activity (10 Years)

Years Active: 2016-2024
Publications (10 Years): 6

Top Topics

Acute Myeloid Leukemia

Ejection Fraction

Top Venues

American journal of hematology

Annals of hematology

British journal of haematology

This page only lists publications with an associated author ORCID identifier.

Publications

Moshe Mittelman, David H Henry, John A Glaspy, Anil Tombak, Rosemary Harrup, Inho Kim, Krzysztof Mądry, Barbara Grabowska, Tyson Lee, Katharina Modelska
Roxadustat versus placebo for patients with lower-risk myelodysplastic syndrome: MATTERHORN phase 3, double-blind, randomized controlled trial. American journal of hematology (2024)
Moshe Mittelman, David H Henry, John A Glaspy, Anil Tombak, Rosemary Harrup, Inho Kim, Krzysztof Mądry, Barbara Grabowska, Tyson Lee, Katharina Modelska
Roxadustat versus placebo for patients with lower-risk myelodysplastic syndrome: MATTERHORN phase 3, double-blind, randomized controlled trial. American journal of hematology 99 (9) (2024)
Pedro Marques Ramos, Jeea Choi, Catarina D Campbell, Ying A Wang, Celine Pallaud, Michael Dickinson, Amit Verma, Moshe Mittelman, Uwe Platzbecker, Honar Cherif, Pierre Fenaux
Next-generation sequencing of baseline genetic mutations and outcomes of eltrombopag and azacitidine therapy in patients with myelodysplastic syndromes and thrombocytopenia: Data from the SUPPORT clinical trial. EJHaem 4 (3) (2023)
Krzysztof Mądry, Karol Lis, Pierre Fenaux, David Bowen, Argiris Symeonidis, Moshe Mittelman, Reinhard Stauder, Jaroslav Čermák, Guillermo Sanz, Eva Hellström-Lindberg, Saskia M C Langemeijer, Luca Malcovati, Ulrich Germing, Mette Skov Holm, Agnes Guerci-Bresler, Dominic Culligan, Laurence Sanhes, Ioannis Kotsianidis, Corine van Marrewijk, Simon Crouch, Theo de Witte, Alexandra G Smith, null null
Cause of death and excess mortality in patients with lower-risk myelodysplastic syndromes (MDS): A report from the European MDS registry. British journal of haematology (2022)
David H Henry, John A Glaspy, Rosemary Harrup, Moshe Mittelman, Amy Zhou, Hetty E Carraway, Charles Bradley, Gopal Saha, Katharina Modelska, Pamela Bartels, Robert Leong, Kin-Hung P Yu
Roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic syndrome: Open-label, dose-selection, lead-in stage of a phase 3 study. American journal of hematology (2021)
Moshe Mittelman, Kalman Filanovsky, Yishai Ofran, Hanna Rosenbaum, Pia Raanani, Andrei Braester, Neta Goldschmidt, Ilya Kirgner, Yair Herishanu, Chava Perri, Martin Ellis, Howard S Oster, null null
Azacitidine-lenalidomide (ViLen) combination yields a high response rate in higher risk myelodysplastic syndromes (MDS)-ViLen-01 protocol. Annals of hematology 95 (11) (2016)